#34 Rosiglitazone – Reasonable Option or Regrettable Choice?
CLINICAL QUESTION
Is rosiglitazone a reasonable second or third line agent in the management of Type 2 Diabetes (DM2)?
BOTTOM LINE
Strong evidence supports increased cardiovascular risk, specifically MI, in Type 2 Diabetes patients receiving rosiglitazone. In the absence of any demonstrated patient-oriented benefits, there is no indication for its use.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
A 2007 meta-analysis (42 randomized controlled trials, 27,847 patients) first assessed the impact of rosiglitazone on cardiovascular (CV) outcomes in DM2 patients.
- Rosiglitazone caused a statistically significant increase in myocardial infarction (MI) over placebo or other drugs, Relative Risk Increase 43% (Confidence Interval (CI) 3%-97%). 1
- No difference in cardiovascular deaths.
- Some questioned the meta-analysis validity due to inclusion of low-quality studies and concern that analysis may have overestimated CV events.2
- 56 trials, 35,531 patients Odds Ratio 1.28 (CI 1.02-1.63), Number Needed to Harm (NNH) 52 over five years. 3
- 52 trials, 16,995 patients Odds Ratio 1.80 (CI 1.03-3.25). 4
- FDA analysis4 found the researchers’ management of some data potentially masked rosiglitazone harms.
- Rosiglitazone was approved based on its ability to improve glycemic control, without any evidence of improvement in patient-oriented outcomes.
- A systematic review reported a strong link between author’s views on rosiglitzone and financial conflicts of interest with manufacturer. 6
- The American Diabetes Association and the European Association for the Study of Diabetes released a consensus statement in 2009 recommending against the use of rosiglitazone in DM2. 7
- In 2013, the FDA relaxed restrictions on rosiglitazone based on re-analysis of the RECORD trial, despite remaining concerns on its safety. 8,9
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Wow!
I don’t use so lucky me 🙂
I do not use but really good to know!
I don’t use so lucky me 🙂
love the bottom line , however it could be extrapolated to some other chronic disease therapies